EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) POLYMORPHIC VARIATIONS (-216G/T & −191 C/A) POSE A HIGH RISK TO PATIENTS WITH MALIGNANT GLIOMA
DOI:
https://doi.org/10.15407/exp-oncology.2023.02.203Keywords:
germline, genetic variants, epidermal growth factor receptor gene, haplotype, glioma, alleleAbstract
Background. Malignant gliomas are the most frequent and lethal brain tumors. Their molecular aspects remain intangible but current studies have pointed to certain genetic polymorphic loci that pose the risk. The polymorphic sequence variations of the epidermal growth factor receptor gene (EGFR) pathway play a vital role in the glioma risk, and the EGFR variants (216G>T and 191C>A) are identified to affect the risk for the development of different tumors including glioma. Aim. To examine genetic variations of EGFR T rs712829 (216G/T) and rs712830 (191C>A) with respect to glioma risk. Materials and Methods. 129 confirmed glioma cases were genotyped against 180 malignancy-free healthy controls by polymerase chain reaction-restriction fragment length polymorphism technique (RFLP). Results. The frequency of the TT homozygous variant of the EGFR -216 G/T genotype differed significantly between cases and controls (49.6% vs. 23.0%) (p < 0.0001). The EGFR -216 G>T allele ‘T’ was found significantly more frequently in cases (0.56 vs. 0.33 in controls; p < 0.0001). The EGFR -191C>A homozygous ‘AA’ genotype was implicated significantly more frequently in cases than in controls (p < 0.0001). The distribution of the ‘A’ variant allele was also more frequent in cases (41.9%) than in controls (14.0%) (0.55 vs. 0.30; p < 0.0001). TC and TA haplotypes showed varied frequency in cases and controls. Conclusion. EGFR -216 G>T and -191 C>A variants and haplotypes (TA and TC) of the EGFR gene are very strong risk factors in the development of glioma in the Kashmiri population.
References
Stupp R, Tonn J-C, Brada M, Pentheroudakis G, Group EGW. High-grade malignant glioma: ESMO Clini- cal Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl_5):v190-v193. doi: 10.1093/annonc/mdq187
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system.
Acta Neuropathol. 2007;114(2):97-109. doi:10.1007/s00401-007-0243-4
Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 2007;114:443-458. doi: 10.1007/s00401-007-0293-7
Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review.
NeuroOncology. 2014;16(7):896-913. doi: 10.1093/neuonc/nou087
Liu Y, Shete S, Hosking FJ, et al. New insights into susceptibility to glioma. Arch Neurol. 2010;67(3):275-278. doi: 10.1001/archneurol.2010.4
Araujo A, Ribeiro R, Azevedo I, et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist. 2007;12(2):201. doi: 10.1634/theoncologist.12-2-201
Zhang Y-M, Cao C, Liang K. Genetic polymorphism of epidermal growth factor 61A> G and cancer risk: a meta- analysis. Cancer Epidemiol. 2010;34(2):150-156. doi: 10.1016/j.canep.2010.02.004
Costa BM, Ferreira P, Costa S, et al. Association between functional EGF+ 61 polymorphism and glioma risk.
Clin Cancer Res. 2007;13(9):2621-2626. doi: 10.1158/1078-0432.ccr-06-2606
Liu W, Innocenti F, Wu MH, et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 2005;65(1):46-53. doi: 10.1158/0008-5472.46.65.1
Costa BM, Viana-Pereira M, Fernandes R, et al. Impact of EGFR genetic variants on glioma risk and patient out- come. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2610-2617. doi: 10.1158/1055-9965.epi-11-0340
Viana-Pereira M, Lopes JM, Little S, et al. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res. 2008;28(2A):913-920. PMID: 18507036
Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci. 1990;87(11):4207- 4211. doi: 10.1073/pnas.87.11.4207
Heimberger AB, Suki D, Yang D, et al. The natural history of EGFR and EGFRvIII in glioblastoma patients.
J Transl Med. 2005;3(1):1-6. doi: 10.1186/1479-5876-3-38
Carpentier C, Laigle-Donadey F, Marie Y, et al. Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastoma. Neurology. 2006;67(5):872-874. doi: 10.1212/01.wnl.0000229927.12007.37
Liu W, Wu X, Zhang W, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007;13(22):6788-6795. doi: 10.1158/1078-0432.ccr-07-0547
Torres-Jasso J, Marín M, Santiago-Luna E, et al. EGFR gene polymorphisms-216G> T and-191C> A are risk mark- ers for gastric cancer in Mexican population. Genet Mol Res. 2015;14(1):1802-1807. doi: 10.4238/2015.march.13.8
Zhang W, Weissfeld JL, Romkes M, et al. Association of the EGFR intron 1 CA repeat length with lung cancer risk. Mol Carcinog. 2007;46(5):372-380. doi: 10.1002/mc.20285
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
